LXEO

Company Overview — What Does Lexeo Therapeutics, Inc. Do?

We are a clinical stage genetic medicine company dedicated to transforming healthcare by applying pioneering science to fundamentally change how disease is treated. By taking aim at the underlying genetic cause of the devastating diseases we target, we seek to create substantial positive impact and reduce the overwhelming burdens placed on people receiving treatment, their caregivers, and healthcare systems. Our current pipeline consists of candidates targeting patient populations that place significant burden on society and are most amenable to our genetic medicine approach. Our most advanced cardiovascular product candidate, LX2006 for the treatment of patients with Friedreich’s ataxia, or FA, cardiomyopathy, is currently being evaluated in an ongoing Phase 1/2 clinical trial. We have observed an increase in frataxin protein expression in the heart from one patient in the low dose cohort based on a cardiac biopsy utilizing two separate analyses. We expect to report additional interim data from this trial in mid-2024. Our second most advanced cardiovascular product candidate, LX2020 for the treatment of arrhythmogenic cardiomyopathy, or ACM, caused by mutations in the PKP2 gene, referred to as PKP2-ACM, received investigational new drug, or IND, clearance from the U.S. Food and Drug Administration, or FDA, in July 2023 and we expect to dose the first patient in a Phase 1/2 clinical trial in the first half of 2024 and provide an interim data readout from cohort 1 in the second half of 2024. Our lead Alzheimer’s disease product candidate, LX1001, for the treatment of APOE4 homozygous patients with Alzheimer’s disease, is in an ongoing Phase 1/2 trial, and we have initially observed an increase in expression levels of the protective protein, APOE2, in the first dose cohort and a consistent trend towards improvement in core Alzheimer’s disease biomarkers. We expect to complete enrollment in the trial by the end of 2023 and report additional interim data from all cohorts in the Phase 1/2 clinical trial in the second half of 2024. We are targeting diseases that have seen limited penetration of precision medicine, which we define as medications that treat the underlying molecular mechanism of a disease, and where we believe there is significant opportunity for gene therapy to play a role as a key therapeutic option. We believe the specific indications we are initially targeting, FA cardiomyopathy, PKP2-ACM and APOE4-associated Alzheimer’s disease, are highly amenable to gene therapy, where administration of a single dose has the potential to either restore loss-of-function or minimize gain-of-function mutations by treating the underlying genetic cause of the disease. Although few precision medicines are currently approved for the treatment of cardiovascular conditions or Alzheimer’s disease, recent approvals by the FDA suggest a willingness to approve new precision medicines based on biomarkers and functional endpoints. Together with improved diagnostics and increased testing, these developments may offer one of the most substantial opportunities for the uptake of precision medicines in the global pharmaceutical marketplace. Each of our gene therapy candidates utilizes the vector construct, dose and route of administration that we believe will result in the most favorable biodistribution and safety profile for our product candidate for each disease. Our most advanced cardiovascular and APOE4-associated Alzheimer’s disease programs use the AAVrh10 vector due to its high transduction efficiency in both myocardial cells and neurons, potential for lower toxicity given the opportunity to utilize lower doses compared to other well-established AAV serotypes, and low pre-existing immunity. By specifically tailoring our technological approach to each targeted disease, we believe we can optimize our programs to achieve the highest likelihood of having therapeutic impact. We target genetically defined indications in specific sub-groups of patients that offer the potential to demonstrate therapeutic impact through improvement in functional endpoints or biomarkers, have high unmet need and large market opportunities, have established proof-of-concept in relevant preclinical models, and have organized patient advocacy groups and identifiable patient populations. In addition to targeting cardiovascular diseases and APOE4-associated Alzheimer’s disease that we believe can be addressed by our current approach utilizing AAVrh10, we have ongoing discovery efforts to identify next-generation vector technologies with the best potential therapeutic profile. Finally, we continuously seek to bolster our pipeline through relationships with academic institutions, providing us access to cutting edge genetic medicines research which will include not only AAV gene therapy but also other potential therapeutic payload types and non-viral delivery systems. In February 2017, we were formed as a Delaware limited liability company under the name LEXEO Therapeutics, LLC. In November 2020, we converted into a Delaware corporation and were renamed Lexeo Therapeutics, Inc. Our principal executive offices are located at 345 Park Avenue South, Floor 6, New York, New York. Lexeo Therapeutics, Inc. (LXEO) is classified as a small-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO R. Nolan Townsend. With a market capitalization of $414M, LXEO is one of the notable companies in the Healthcare sector.

Lexeo Therapeutics, Inc. (LXEO) Stock Rating — Reduce (April 2026)

As of April 2026, Lexeo Therapeutics, Inc. receives a Reduce rating with a composite score of 30.3/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.LXEO ranks #3,701 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Lexeo Therapeutics, Inc. ranks #612 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

LXEO Stock Price and 52-Week Range

Lexeo Therapeutics, Inc. (LXEO) currently trades at $6.43. The 52-week high for LXEO is $10.99, which means the stock is currently trading -41.5% from its annual peak. The 52-week low is $1.45, putting the stock 343.4% above its annual trough. Recent trading volume was 0 shares, suggesting relatively thin trading activity.

Is LXEO Overvalued or Undervalued? — Valuation Analysis

Lexeo Therapeutics, Inc. (LXEO) carries a value factor score of 17/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 1.90x, versus the sector average of 2.75x.

At current multiples, Lexeo Therapeutics, Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Lexeo Therapeutics, Inc. Profitability — ROE, Margins, and Quality Score

Lexeo Therapeutics, Inc. (LXEO) earns a quality factor score of 27/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -44.0%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -40.4% versus the sector average of -33.1%.

Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

LXEO Debt, Balance Sheet, and Financial Health

Lexeo Therapeutics, Inc. has a debt-to-equity ratio of 9.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 11.21x, indicating strong short-term liquidity. Total debt on the balance sheet is $0. Cash and equivalents stand at $41M.

LXEO has a beta of 2.28, meaning it is more volatile than the broader market — a $10,000 investment in LXEO would be expected to move 128.1% more than the S&P 500 on any given day. The stability factor score for Lexeo Therapeutics, Inc. is 18/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

Lexeo Therapeutics, Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, Lexeo Therapeutics, Inc. reported revenue of $0 and earnings per share (EPS) of $-1.86. Net income for the quarter was $-109M. Operating income came in at $-118M.

In FY 2025, Lexeo Therapeutics, Inc. reported revenue of $0 and earnings per share (EPS) of $-1.86. Net income for the quarter was $-100M. Operating income came in at $-109M.

In Q3 2025, Lexeo Therapeutics, Inc. reported revenue of $0 and earnings per share (EPS) of $-0.33. Net income for the quarter was $-20M. Operating income came in at $-22M.

In Q2 2025, Lexeo Therapeutics, Inc. reported revenue of $0 and earnings per share (EPS) of $-0.60. Net income for the quarter was $-26M. Operating income came in at $-31M.

Over the past 8 quarters, Lexeo Therapeutics, Inc. has experienced revenue contraction from $0 to $0. Investors analyzing LXEO stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

LXEO Dividend Yield and Income Analysis

Lexeo Therapeutics, Inc. (LXEO) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

LXEO Momentum and Technical Analysis Profile

Lexeo Therapeutics, Inc. (LXEO) has a momentum factor score of 47/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 25/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 37/100 signals elevated short interest, which can indicate bearish sentiment among institutional investors.

LXEO vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Lexeo Therapeutics, Inc. (LXEO) ranks #612 out of 838 stocks based on the Blank Capital composite score. This places LXEO in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing LXEO against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full LXEO vs S&P 500 (SPY) comparison to assess how Lexeo Therapeutics, Inc. stacks up against the broader market across all factor dimensions.

LXEO Next Earnings Date

No upcoming earnings date has been announced for Lexeo Therapeutics, Inc. (LXEO) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy LXEO? — Investment Thesis Summary

The quantitative profile for Lexeo Therapeutics, Inc. suggests caution. The quality score of 27/100 flags below-average profitability. The value score of 17/100 indicates premium valuation. High volatility (stability score 18/100) increases portfolio risk.

In summary, Lexeo Therapeutics, Inc. (LXEO) earns a Reduce rating with a composite score of 30.3/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on LXEO stock.

Related Resources for LXEO Investors

Explore more research and tools: LXEO vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare LXEO head-to-head with peers: LXEO vs AZN, LXEO vs SLGL, LXEO vs VMD.